Two studies in this issue identify the landscape of somatic mutations in Burkitt lymphoma and highlight the pathogenic and clinical relevance of inactivating mutations of ID3, an inhibitor of the TCF3 transcription factor.
This is a preview of subscription content, log in via an institution to check access.
Debbie Maizels
References
Wright, D. Br. J. Haematol. 156, 780–782 (2012).
Dalla-Favera, R. et al. Proc. Natl. Acad. Sci. USA 79, 7824–7827 (1982).
Magrath, I. Br. J. Haematol. 156, 744–756 (2012).
Janz, S. et al. Genes Chrom. Cancer 36, 211–223 (2003).
Richter, J. et al. Nat. Genet. 44, 1316–1320 (2012).
Love, C. et al. Nat. Genet. 44, 1321–1325 (2012).
Schmitz, R. et al. Nature 490, 116–120 (2012).
Seitz, V. et al. PLoS One 6, e26837 (2011).
Sander, S. Cancer Cell 22, 167–179 (2012).
Victora, G.D. et al. Blood 120, 2240–2248 (2012).
Salaverria, I. & Siebert, R. J. Clin. Oncol. 29, 1835–1843 (2011).
Molyneux, E.M. et al. Lancet 379, 1234–1244 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Campo, E. New pathogenic mechanisms in Burkitt lymphoma. Nat Genet 44, 1288–1289 (2012). https://doi.org/10.1038/ng.2476
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2476
- Springer Nature America, Inc.
This article is cited by
-
A modular transcriptome map of mature B cell lymphomas
Genome Medicine (2019)
-
Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells
Frontiers of Medicine (2018)
-
Burkitt lymphoma research in East Africa: highlights from the 9th African organization for research and training in cancer conference held in Durban, South Africa in 2013
Infectious Agents and Cancer (2014)
-
Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience
Current Hematologic Malignancy Reports (2013)